Loading publications…
The last 5 uploaded publications
FDG-PET associations with pathological response and survival with neoadjuvant immunotherapy for melanoma
Li Zhou, Milton Barros, Edward Hsiao, Zeynep Eroglu, Shahneen Sandhu, Igor Samoylenko, Serigne Lo, Matteo S Carlino, George Au‐Yeung, Maria Gonzalez, Andrew J. Spillane, Thomas E Pennington, Kerwin F Shannon, Rony Kapoor, Elizabeth M. Burton, Hussein A. Tawbi, Rodabe N. Amaria, Christian U. Blank, João Pedreira Duprat Neto, Rafaela Brito de Paula, David E Gyorki, R.P.M. Saw, Sydney Ch'ng, Robert V. Rawson, Richard A. Scolyer, Inês Pires da Silva, Alexander C J van Akkooi, Georgina V Long, Alexander M. Menzies (2025). FDG-PET associations with pathological response and survival with neoadjuvant immunotherapy for melanoma. , 13(3), DOI: https://doi.org/10.1136/jitc-2025-011483.
Article62 days agoOverall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial
Michael S. Hofman, Louise Emmett, Shahneen Sandhu, Amir Iravani, James Buteau, Anthony M. Joshua, Jeffrey C. Goh, David A. Pattison, Thean Hsiang Tan, Ian Kirkwood, Siobhan Ng, Roslyn J. Francis, Craig Gedye, Natalie Rutherford, Andrew Weickhardt, Andrew M. Scott, Sze-Ting Lee, Edmond M. Kwan, Arun Azad, Shakher Ramdave, Andrew D. Redfern, W A Macdonald, Alex Guminski, Edward Hsiao, Wei Chua, Peter Lin, Alison Yan Zhang, Martin R. Stockler, Scott Williams, Andrew Martin, Ian D. Davis, Tim Akhurst, Ramin Alipour, Dale L. Bailey, Patricia Banks, Alexis Beaulieu, Louise Campbell, Megan Crumbaker, Nattakorn Dhiantravan, Anis Hamid, Mohammad B. Haskali, Terry Hung, Grace Kong, Nick Lawrence, Jeremy Lewin, Michael McCarthy, Kate Moodie, Declan G. Murphy, Andrew Nguyen, David Pook, Aravind Ravi Kumar, Paul Roach, Peter Roselt, Javad Saghebi, Geoffrey Schembri, Lavinia Spain, Shalini Subramaniam, Sue Ping Thang, Paul Thomas, Ben Tran, Roslyn E. Wallace, Sonia Yip (2023). Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial. , 25(1), DOI: https://doi.org/10.1016/s1470-2045(23)00529-6.
Article62 days agoPSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial
James Buteau, Andrew Martin, Louise Emmett, Amir Iravani, Shahneen Sandhu, Anthony M. Joshua, Roslyn J. Francis, Alison Y. Zhang, Andrew M. Scott, Sze-Ting Lee, Arun Azad, Margaret McJannett, Martin R. Stockler, Scott Williams, Ian D. Davis, Michael S. Hofman, Tim Akhurst, Ramin Alipour, Arun Azad, Patricia Banks, Alexis Beaulieu, James Buteau, Wei Chua, Ian D. Davis, Nattakorn Dhiantravan, Louise Emmett, Kate Ford, Michael S. Hofman, Roslyn J. Francis, Craig Gedye, Jeffrey C. Goh, Alex Guminski, Anis Hamid, Mohammad B. Haskali, Rodney J. Hicks, Edward Hsiao, Amir Iravani, Anthony M. Joshua, Ian Kirkwood, Grace Kong, Edmond M. Kwan, Ailsa Langford, Nicola Jane Lawrence, Sze-Ting Lee, Jeremy Lewin, Peter Lin, Andrew Martin, William M. McDonald, Margaret McJannett, Kate Moodie, Declan G. Murphy, Siobhan Ng, David A. Pattison, Izabella Pokorski, Shakher Ramdave, Aravind S. Ravi Kumar, Andrew D. Redfern, Natalie Rutherford, Javad Saghebi, Shahneen Sandhu, Andrew M. Scott, Lavinia Spain, Martin R. Stockler, Shalini Subramaniam, Thean Hsiang Tan, Sue Ping Thang, Ben Tran, Roslyn E. Wallace, Andrew Weickhardt, Scott Williams, Sonia Yip, Alison Y. Zhang (2022). PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial. , 23(11), DOI: https://doi.org/10.1016/s1470-2045(22)00605-2.
Article62 days agoPSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial
James Buteau, Andrew Martin, Louise Emmett, Amir Iravani, Shahneen Sandhu, Anthony M. Joshua, Roslyn J. Francis, Alison Y. Zhang, Andrew M. Scott, Sze-Ting Lee, Arun Azad, Margaret McJannett, Martin R. Stockler, Scott Williams, Ian D. Davis, Michael S. Hofman, Tim Akhurst, Ramin Alipour, Arun Azad, Patricia Banks, Alexis Beaulieu, James Buteau, Wei Chua, Ian D. Davis, Nattakorn Dhiantravan, Louise Emmett, Kate Ford, Michael S. Hofman, Roslyn J. Francis, Craig Gedye, Jeffrey C. Goh, Alex Guminski, Anis Hamid, Mohammad B. Haskali, Rodney J. Hicks, Edward Hsiao, Amir Iravani, Anthony M. Joshua, Ian Kirkwood, Grace Kong, Edmond M. Kwan, Ailsa Langford, Nicola Jane Lawrence, Sze-Ting Lee, Jeremy Lewin, Peter Lin, Andrew Martin, William M. McDonald, Margaret McJannett, Kate Moodie, Declan G. Murphy, Siobhan Ng, David A. Pattison, Izabella Pokorski, Shakher Ramdave, Aravind S. Ravi Kumar, Andrew D. Redfern, Natalie Rutherford, Javad Saghebi, Shahneen Sandhu, Andrew M. Scott, Lavinia Spain, Martin R. Stockler, Shalini Subramaniam, Thean Hsiang Tan, Sue Ping Thang, Ben Tran, Roslyn E. Wallace, Andrew Weickhardt, Scott Williams, Sonia Yip, Alison Y. Zhang (2022). PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial. , 23(11), DOI: https://doi.org/10.1016/s1470-2045(22)00605-2.
Article62 days ago[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
Michael S. Hofman, Louise Emmett, Shahneen Sandhu, Amir Iravani, Anthony M. Joshua, Jeffrey C. Goh, David A. Pattison, Thean Hsiang Tan, Ian Kirkwood, Siobhan Ng, Roslyn J. Francis, Craig Gedye, Natalie Rutherford, Andrew Weickhardt, Andrew M. Scott, Sze-Ting Lee, Edmond M. Kwan, Arun Azad, Shakher Ramdave, Andrew D. Redfern, W A Macdonald, Alex Guminski, Edward Hsiao, Wei Chua, Peter Lin, Alison Y. Zhang, Margaret McJannett, Martin R. Stockler, John Violet, Scott Williams, Andrew Martin, Ian D. Davis, Arun Azad, Wei Chua, Ian D. Davis, Nattakorn Dhiantravan, Louise Emmett, Kate Ford, Michael S. Hofman, Roslyn J. Francis, Craig Gedye, Jeffrey C. Goh, Alex Guminski, Edward Hsiao, Amir Iravani, Anthony M. Joshua, Ian Kirkwood, Ailsa Langford, Nicola Jane Lawrence, Sze-Ting Lee, Peter Lin, Andrew Martin, William M. McDonald, Margaret McJannett, Siobhan Ng, David A. Pattison, Shakher Ramdave, Nisha Rana, Andrew D. Redfern, Natalie Rutherford, Shahneen Sandhu, Andrew M. Scott, Martin R. Stockler, Shalini Subramaniam, Thean Hsiang Tan, John Violet, Andrew Weickhardt, Scott Williams, Sonia Yip, Alison Y. Zhang (2021). [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. , 397(10276), DOI: https://doi.org/10.1016/s0140-6736(21)00237-3.
Article62 days ago